Journal Article

P.3. Basic Science, Sudden Death Risk Stratification and Ventricular Arrhythmias

I. Kanki, K. Kajimoto, M. Shoda, N. Hagiwara, J. Umemura and H. Kasanuki

in EP Europace

Published on behalf of European Heart Rhythm Association of the European Society of Cardiology (ESC)

Volume 7, issue s3, pages S51-S52
Published in print October 2005 | ISSN: 1099-5129
Published online October 2005 | e-ISSN: 1532-2092 | DOI: https://dx.doi.org/10.1016/j.eupc.2005.08.214
P.3. Basic Science, Sudden Death Risk Stratification and Ventricular Arrhythmias

Show Summary Details

Preview

Background

In Arrhythmogenic right ventricular cardiomyopathy (ARVC), 10-year sudden cardiac death (SCD) rate of 15-25% has been reported. Many recent propers have supported active implantation of implantable cardioverter defibrillator (ICD), but the efficacy and outcome of drug therapy and catheter ablation (CA) have not been evaluated adequately.

Subjects and Methods

Among 45 patients (38 males, 7 females) diagnosed as affected by ARVC, drug therapy and CA were considered effective for treating VT/VF in 38 patients (32 males, 6 females). Rehospitalization and cardiac mortality (heart failure death or SCD) were evaluated in these patients. Moreover, ICD intervention was examined in 7 patients implanted with ICD.

Results

Of the 38 patients, 3 were treated with class I antiarrhythmic drugs, 12 with amiodarone, 7 with CA alone, and 16 with CA plus drug therapy. The mean follow-up was 8.7±11.4 years. The patients were readmitted on average 1.6±4.6 times. There were 2 heart failure deaths and 1 SCD. Among the 7 of 45 patients implanted with ICD, an appropriate ICD therapy for VT/VF was observed in one patient.

Conclusion

Our results suggest that for patients with VT/VF secondary to ARVC, starting drug therapy and CA is important to prevent SCD associated with ARVC.

Journal Article.  0 words. 

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.